Dasher Neuroscience Completes Patient Enrollment in Phase 2 Global Clinical Trial of Lead AI Drug Candidate YA-101 for Multiple System Atrophy (MSA)

Phase 2YA-101Positive

AI Analysis

Summary

Dasher Neuroscience has completed patient enrollment in a Phase 2 global clinical trial of YA-101, an AI-derived drug candidate for Multiple System Atrophy. The company's advancement of this lead CNS program represents a routine clinical development milestone.

Clinical Trial Data

Phase

Phase 2

Outcome Details

Patient enrollment completed

Importance:5/10

Sentiment:

0.60

AI-driven drug discoveryCNS focusPhase 2 enrollmentMultiple System Atrophy

Related Companies

$GBCYD

Read the original article

Published by PR Newswire Biotech on July 28, 2026 12:12 PM

Read Original